Innovative R&D Platform NemaLife offers an AI-assisted microfluidics in vivo platform based on C. elegans, providing a cruelty-free, cost-effective, and rapid alternative to traditional animal models. This technology appeals to companies seeking to accelerate early-stage discovery and product development in biotech, nutraceuticals, and pharma sectors.

Recent Funding & Support Receiving a grant from the National Institutes of Health highlights strong validation and potential for growth, especially in developing probiotics and postbiotics, which presents opportunities to collaborate with organizations focused on human health innovations.

Expanding AI Capabilities The launch of new AI tools designed for functional ingredient analysis opens doors for partnerships with supplement and functional food companies looking to streamline their R&D processes and accelerate market entry of new ingredients.

Strategic Industry Collaborations Partnerships with industry players like Motif FoodWorks demonstrate NemaLife’s value as an in vivo testing platform, positioning it to expand collaborations in food tech, gut health, and aging products—key areas with high market growth potential.

Recognition & Market Position Winning the 2022 Startup of the Year Award from Texas Tech University enhances credibility and visibility in the biotech research community, making NemaLife a compelling partner for companies seeking innovative pre-clinical testing solutions.